Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candidate and filing today with U.S. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. Understanding mRNA COVID-19 vaccines.īaden LR, El Sahly HM, Essink B, et al. doi:10.1038/nrd.2017.243Ĭenters for Disease Control and Prevention. mRNA vaccines - a new era in vaccinology. Pardi N, Hogan MJ, Porter FW, Weissman D. Biden administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna. doi:10.1056/NEJMoa2022483ĭepartment of Health and Human Services. An mRNA vaccine against SARS-CoV-2-preliminary report. Jackson LA, Anderson EJ, Rouphael NG, et al. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.Food and Drug Administration. NASDAQ data is at least 15 minutes delayed. ![]() NYSE and AMEX data is at least 20 minutes delayed. Real time prices by BATS. Delayed quotes by FIS. Visit to get our data and content for your mobile app or website. Visit Performance Disclosure for information about the performance numbers displayed above. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The monthly returns are then compounded to arrive at the annual return. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. These returns cover a period from Januthrough May 15, 2023. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. ![]() and Morningstar, Inc.Ĭopyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc. ![]() Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. However, the FDA is yet to approve/authorize either Novavax’s or Pfizer/BioNTech’s vaccine. Novavax stated that it is currently manufacturing its protein-based monovalent XBB.1.5 COVID vaccine candidate at a commercial scale, intended to be in the market during the 2023 fall vaccination campaign. Pfizer/BioNTech expects to make their updated vaccine ready for supply by the end of next month. The preclinical data from these manufacturers indicate that a monovalent vaccine is more effective against a bivalent vaccine. During the FDA committee meeting held last week, Pfizer/BioNTech, Moderna and Novavax presented their pre-clinical findings supporting the use of their own vaccines, which target the XBB.1.5 variant. The submission follows the guidance from an FDA advisory committee issued last week, which unanimously recommended updating the COVID vaccine to target the Omicron XBB lineage, which is currently responsible for the majority of the COVID infections in the country.Īpart from Moderna, other COVID vaccine makers like Pfizer ( PFE Quick Quote PFE - Free Report) / BioNTech ( BNTX Quick Quote BNTX - Free Report) and Novavax ( NVAX Quick Quote NVAX - Free Report) are also updating their own vaccines to target the XBB lineages. Shares of Moderna have lost 32.9% year to date compared with the industry’s 7.6% fall. Management claims that it has built an ample supply for mRNA-1273.815 and is ready to ship doses of the same for the fall vaccination season, provided that the FDA authorizes the vaccine for use. The regulatory filing is based on preliminary data from preclinical studies that demonstrated the effectiveness of mRNA-1273.815 in generating an immune response against the current XBB variants of concern. ![]() Unlike the currently-authorized COVID-19 vaccines that are bivalent in nature and target multiple strains of coronavirus, mRNA-1273.815 is a monovalent vaccine containing spike proteins for the XBB.1.5 sublineage of coronavirus. Moderna ( MRNA Quick Quote MRNA - Free Report) announced that it has submitted a regulatory application to the FDA seeking approval for mRNA-1273.815, its updated COVID-19 vaccine targeting the XBB descendent lineage viruses.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |